CHRISTIANNA BULL: Open Payments
NPI 1477306603 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,454 in 64 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $383 · 2025 $1,454
Food & beverage: $1,454
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 2 | $246 |
| Teva Pharmaceuticals USA, Inc. | 12 | $179 |
| Alkermes, Inc. | 9 | $159 |
| Lundbeck LLC | 9 | $159 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| Vanda Pharmaceuticals Inc. | 4 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $99 |
| Gilead Sciences, Inc. | 4 | $87 |
| ABBVIE INC. | 2 | $56 |
| Axsome Therapeutics, Inc. | 2 | $48 |
Products named: REPATHA, REXULTI, ARISTADA, UZEDY, CAPLYTA, ABILIFY MAINTENA, HETLIOZ, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
